Evidence map›Paper›PMID 40376612›Full record

ArticleFrontiers in neuroscience2025

Dose-dependent changes in global brain activity and functional connectivity following exposure to psilocybin: a BOLD MRI study in awake rats.

Evan Fuini, Arnold Chang, Richard J Ortiz, Taufiq Nasseef, Josh Edwards, Marc Latta, Elias Gonzalez, Taylor J Woodward, Bryce Axe, Ashwath Maheswari and 4 more

Abstract read
In one paragraph

Article in Frontiers in neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Evan FuiniDepartment Pharmaceutical Sciences, Northeastern University, Boston, MA, United States.
Arnold ChangCenter for Translational Neuroimaging, Northeastern University, Boston, MA, United States.
Richard J OrtizDepartment of Chemistry & Biochemistry, New Mexico State University, Las Cruces, NM, United States.
Taufiq NasseefDepartment of Mathematics, College of Science & Humanity Studies, Riyadh, Saudi Arabia.
Josh EdwardsDepartment Pharmaceutical Sciences, Northeastern University, Boston, MA, United States.
Marc LattaDepartment Pharmaceutical Sciences, Northeastern University, Boston, MA, United States.
Elias GonzalezDepartment Pharmaceutical Sciences, Northeastern University, Boston, MA, United States.
Taylor J WoodwardPsychological & Brain Sciences, Program in Neuroscience, Indiana University, Bloomington, IN, United States.
Bryce AxeDepartment Pharmaceutical Sciences, Northeastern University, Boston, MA, United States.
Ashwath MaheswariDepartment Pharmaceutical Sciences, Northeastern University, Boston, MA, United States.
Noah CavallaroDepartment Pharmaceutical Sciences, Northeastern University, Boston, MA, United States.
Heather B BradshawPsychological & Brain Sciences, Program in Neuroscience, Indiana University, Bloomington, IN, United States.
Praveen P KulkarniCenter for Translational Neuroimaging, Northeastern University, Boston, MA, United States.
Craig F FerrisCenter for Translational Neuroimaging, Northeastern University, Boston, MA, United States.

Funding

Multi-Scale Imaging Core (MSIC)P30DA056410 · NIDA · TRUSTEES OF INDIANA UNIVERSITY · PI Kenneth Mackie · 2023 to 2026
$7.1M
NIDA NIH HHS P30 DA056410
6 · The paper itself

Abstract

Psilocybin is a hallucinogen with complex neurobiological and behavioral effects. This is the first study to use MRI to follow functional changes in brain activity in response to different doses of psilocybin in fully awake, drug naive rats. We hypothesized that psilocybin would show a dose-dependent increase in activity in the prefrontal cortex and thalamus, while decreasing hippocampal activity. Female and male rats were given IP injections of vehicle or psilocybin in doses of 0.03 mg/kg, 0.3 mg/kg, and 3.0 mg/kg while fully awake during the imaging session. These levels were validated by measuring psilocybin and its metabolite, psilocin. Changes in BOLD signal were recorded over a 20 min window. Data for resting state functional connectivity were collected approximately 35 min post injection. All data were registered to rat 3D MRI atlas with 169 brain areas providing site-specific changes in global brain activity and changes in functional connectivity. Treatment with psilocybin resulted in a significant dose-dependent increase in positive BOLD signal. The areas most affected by the acute presentation of psilocybin were the somatosensory cortex, basal ganglia and thalamus. Males and females showed different sensitivity to psilocybin dose, with females exhibiting greater activation than males at 0.3 mg/kg, especially in thalamic and basal ganglia regions. There was a significant dose-dependent global increase in functional connectivity, highlighted by hyperconnectivity to the cerebellum. Brain areas hypothesized to be involved in loss of sensory filtering and organization of sensory motor stimuli, such as the cortico-striato-thalamo-cortical circuit and the claustrum, showed increased activation at higher doses of psilocybin. Indeed, the general neuroanatomical circuitry associated with the psychedelic experience was affected but the direction of the BOLD signal and pattern of activity between neural networks was inconsistent with the human literature.

Indexed as

5-HT2A receptorBOLD resting state functional connectivitycerebellar nucleihyperconnectivitypsilocin

Identifiers

PMID40376612
PMCPMC12078138

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.